Fri. 23 Feb 2024, 8:31am ET
Benzinga
Biotech, News, General
Biodexa Reports Phase I Clinical Trial of MTX110 Shows Median Survival of 16.5 Months in DMG Patients, Inconclusive Tolimidone Results in Beta Cell Proliferation Study
On the Company's behalf, a CRO conducted an in vitro experiment designed to demonstrate tolimidone's potential for beta cell proliferation using reaggregated pancreatic islets. The results of the experiment were inconclusive in that they did not correlate with the results previously seen in in vitro and in vivo studies of tolimidone.